All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Monoclonal antibodies target antigens expressed by malignant cells, making them more selective than chemotherapy. Antibodies can induce the innate immune response to destroy tumor cells, or block key extracellular sites such as receptors to induce cancer cell death. In MM, target antigens include BCMA, CD20, CD38, CD40, PD-1, and VEGF.
Save to your areas of interest